Dr Han Hsi Wong

Cambridge University Hospitals NHS Foundation Trust

University departments: 
Department of Oncology

Position: Consultant Medical Oncologist
Personal home page: https://www.researchgate.net/profile/Han-Wong-3

PubMed journal articles - click here

Research description: 

Treatment of bone and soft-tissue sarcomas and testicular (germ cell) cancer.

Research Programme or Virtual Institute: 
Paediatric Cancer
Tumour type interests: 
Bone and connective tissue
Testis

Key publications: 

Peer-reviewed journals

  1. Wong HH, Cojocaru E, Watkins J, et al. Radiation-induced angiosarcoma of the breast: retrospective analysis at a regional treatment centre. Breast Cancer. 2024;31(2):272-82. Available at https://rdcu.be/duxwc
  2. Lloyd P, Hong A, Furrer MA, et al. A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections. World J Urol. 2022;40(1):119-26.
  3. Wong HH, Bentley H, Bulusu VR, et al. Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib. Anticancer Drugs. 2020;31(10):1106-10.
  4. Doherty GJ, Davidson D, Wong HH, Hatcher HM. Cardiotoxicity with trabectedin in the treatment of advanced soft tissue sarcoma. Anticancer Drugs. 2019;30(1):110-5.
  5. Weaver HL, Preston SD, Wong HH, et al. Surgical resection of a massive primary mediastinal liposarcoma with cervical extension. Ann R Coll Surg Engl. 2018;100(2):e22-e27.
  6. Boulos S, Mazhar D, Warren AY, Wong HH. Adjuvant chemotherapy and follow-up for recurrences in localized testicular cancer. Future Oncol. 2017;13(11):947-50.
  7. Szucs Z, Messiou C, Wong HH, et al. Pazopanib, a promising option for the treatment of aggressive fibromatosis. Anticancer Drugs. 2017;28(4):421-426.
  8. Wong HH, Barton C, Acton G, et al. Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: the Cancer Research UK experience. Eur J Cancer. 2016;66:9-16.
  9. Szucs Z, Davidson D, Wong HH, et al. A comprehensive single institutional review of 2 years in a designated fast-track sarcoma diagnostic clinic linked with a Sarcoma Specialist Advisory Group: meeting the target but failing the task? Sarcoma. 2016;2016:6032606.
  10. Wong HH, Halford S. Dose-limiting toxicity and maximum tolerated dose: still fit for purpose? Lancet Oncol. 2015;16(13):1287-8.
  11. Ghorani E, Wong HH, Hewitt C, et al. Safety and efficacy of modified FOLFIRINOX for advanced pancreatic adenocarcinoma: a UK single-centre experience. Oncology. 2015;89(5):281-7.
  12. Wong HH, Gounaris I, McCormack A, et al. Presentation and management of pulmonary artery sarcoma. Clin Sarcoma Res. 2015;5(1):3.
  13. Wong HH, Collins J, McAdam K, Wilson C. Trastuzumab beyond progression in advanced breast cancer: national guidance versus oncologist’s decision. Oncology. 2014;86(1):22-3.
  14. Wong HH, Hatcher HM, Benson C, et al. Desmoplastic small round cell tumours: characteristics and prognostic factors of 41 patients and review of the literature. Clin Sarcoma Res. 2013;3(1):14.
  15. Wong HH, Siegler C, Grainger S, et al. Improving clinical trial recruitment: experience of a tertiary renal oncology centre. Oncology. 2013;85(5):297-8.
  16. Wong HH, Eisen T. Tivozanib for the treatment of metastatic renal cancer. Expert Rev Anticancer Ther. 2013;13(6):649-60.
  17. Wong HH, Parkinson C, Ledermann JA, et al. Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation. Gynecol Oncol Case Rep. 2012;3:7-10.
  18. Wong HH, Jiang G, Gangeswaran R, et al. Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11. Mol Ther. 2012;20(2):306-16.
  19. Jiang G, Cao F, Ren G, et al. PRSS3 promotes tumour growth and metastasis of human pancreatic cancer. Gut. 2010;59(11):1535-44.
  20. Wong HH, Lemoine NR. Novel therapies for pancreatic cancer: setbacks and progress. Future Oncol. 2010;6(7):1061-4.
  21. Wong HH, Lemoine NR, Wang Y. Oncolytic viruses for cancer therapy: overcoming the obstacles. Viruses. 2010;2(1):78-106.
  22. Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol. 2009;6(7):412-22.
  23. Danovi SA, Wong HH, Lemoine NR. Targeted therapies for pancreatic cancer. Br Med Bull. 2008;87:97-130.
  24. Wong HH, Lemoine NR. Biological approaches to therapy of pancreatic cancer. Pancreatology. 2008;8(4-5):431-61.

 

Book chapters

  1. Wong HH, Greef B, Eisen T. Treatment of metastatic renal cancer. In: Hamdy F, Eardley I, editors. Oxford textbook of urological surgery. Oxford: Oxford University Press; 2017. p 757-75.
  2. Ghorani E, Wong HH, Buscombe J, et al. Current management of gastroenteropancreatic neuroendocrine tumours. In: Shrikhande SV, Sirohi B, editors. Modern gastrointestinal oncology. India: Elsevier; 2015. p. 424-443.
  3. Wong HH, Eisen T. First-generation tyrosine kinase inhibitors: clinical results. In: Bukowski RM, Figlin RA, Motzer R, editors. Renal cell carcinoma: molecular targets and clinical application. 3rd ed. New York: Springer; 2015. p. 177-205.
  4. Hallden G, Wang Y, Wong HH, Lemoine NR. Oncolytic adenoviruses for cancer gene therapy. In: Scherman D, editor. Advanced textbook on gene transfer, gene therapy and genetic pharmacology: principles, delivery and pharmacological and biomedical applications of nucleotide-based therapies. London: Imperial College Press; 2014. p. 307-329.
  5. Wong HH, Lemoine NR. Gene therapy for pancreatic cancer. In: Neoptolemos JP, Urrutia R, Abbruzzese JL, Büchler MW, editors. Pancreatic cancer. New York: Springer; 2010. p. 1237-68.